Description
The interaction of cancer with the immune microenvironment, and the potential for its use in cancer treatment, is of rapidly growing importance in the current forefront of cancer research. Monoclonal antibodies, checkpoint inhibitors, and cell based therapies, such as Chimeric Antigen Receptor (CAR) T-cells, are now being routinely used as standard treatment for certain cancer types, while clinical trials are exploring the targeting of innate immune cells such as Dendritic Cells or Natural Killer cells,. There is vast potential for cancer immunotherapies to produce highly effective treatment responses, targeting tumour cells all-round the body, and for some therapy types producing cancer-specific immunological memory.
This module will explore the interplay of tumour cells with tumour infiltrating immune cells and will investigate the anti- and pro-tumorigenic pathways that this can activate, and the mechanisms of immune surveillance and immune evasion. The module will also examine different immunotherapeutic approaches to cancer treatment and the engineering of cell-based immunotherapies.
Module deliveries for 2024/25 academic year
Last updated
This module description was last updated on 19th August 2024.
Ìý